
The FDA has approved Novartis' Cosentyx (secukinumab) 150 mg for treating adults with polymyalgia rheumatica (PMR) who do not respond well to or cannot tolerate corticosteroids. This marks the first anti-IL-17 biologic approved for PMR, offering a new option beyond steroids, which have significant side effects. The approval is based on the Phase III REPLENISH trial showing Cosentyx doubled sustained remission rates and helped reduce steroid use. Novartis aims to expand Cosentyx's benefits to PMR patients, addressing a significant unmet medical need.
Novartis AG shares are trading at USD 160.16 on Pluang, down 0.21% as of Nov 17, 2026 10:02 WIB. The stock has a dividend yield of 2.95% and a market cap of $302.83 billion at this time.